Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other financing activities (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Other financing activities for 4 consecutive years, with -$415000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 149.64% to -$415000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72000.0 through Dec 2025, down 94.76% year-over-year, with the annual reading at $72000.0 for FY2025, 94.76% down from the prior year.
  • Other financing activities hit -$415000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $487000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.7 million in Q1 2021 to a low of -$415000.0 in Q4 2025.
  • Historically, Other financing activities has averaged $686833.3 across 3 years, with a median of $512500.0 in 2024.
  • Biggest five-year swings in Other financing activities: surged 267500.0% in 2021 and later crashed 149.64% in 2025.
  • Year by year, Other financing activities stood at -$1000.0 in 2021, then skyrocketed by 83700.0% to $836000.0 in 2024, then plummeted by 149.64% to -$415000.0 in 2025.
  • Business Quant data shows Other financing activities for IMDX at -$415000.0 in Q4 2025, $487000.0 in Q1 2025, and $836000.0 in Q4 2024.